NCT02179372已完成不适用
Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- changes in fecal calprotectin levels
研究概览
简要总结
The aim of this study is to test Eicosapentaenoic free fatty acid's effects on calprotectin levels in IBD patients in clinical remission. During the study fecal calprotectin levels will be measured every 3 months and clinical flares will be registered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ranged between18 and 80 years.
- •Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic and histologic criteria) in clinical remission (SCCAI = 0) from at least 3 months and in stable therapy (without therapeutic modifications in the three previous months) with 5-ASA, immunomodulators and/or biologics.
- •Patients affected by Crohn's Disease (diagnosed on the base of clinic, endoscopic and histologic criteria) ) in clinical remission (CDAI < 150) from at least 3 months and in stable therapy (without therapeutic modifications in the three previous months) with 5-ASA, immunomodulators and/or biologics.
- •Fecal calprotectin at baseline > 150 μg/g.
排除标准
- •Patients affected by Ulcerative Colitis and Crohn's Disease respectively with a SCCAI ≥ 1 and a CDAI ≥
- •Patients on steroid therapy.
- •Patients in therapy wih warfarin or other anticoagulants.
- •Known or supposed ipersensitivity to eicosapentaenoic acid/omega
- •Women in fertile age which refuse to use contracceptives specified in the study (oral contraception, IUD) and breastfeed women.
- •Patients with severe clinical conditions which the investigator consider to controindicate patient partecipation at the study.
- •Therapy modifications and/or assumption of sperimental therapies within three months before the study inclusion.
- •Patients unable to follow protocol procedures and to sign the informate consent.
结局指标
主要结局
changes in fecal calprotectin levels
时间窗: baseline, 3 months and at 6 months
次要结局
- number of clinical flares of diseases(at 6 months)
研究者
andrea belluzzi, MD phD
Consultant in Gastroenterology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal CancerUlcerative ColitisNCT02069561IRCCS Azienda Ospedaliero-Universitaria di Bologna25
已完成
不适用
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB PatientsMuscular Dystrophy, DuchenneNCT01826422Coordinación de Investigación en Salud, Mexico40
招募中
不适用
A study on the effects of eicosapentaenoic acid (EPA) on arteriosclerosis in hemodialysis patients with percutaneous coronary intervention (PCI)Dialysis patients who have been subjected to PCI.JPRN-UMIN000002653agoya Kyoritsu Hospital100
已完成
不适用
Efficacy of eicosapentaenoic acid on the prevention of preterm birth in women with cervical shorteningthreatened preterm deliveryJPRN-UMIN000027997The University of Tokyo Hospital99
终止
不适用
Effect of Fish Oil on Athlete's Executive FunctionBrain HealthBrain FunctionBrain DevelopmentNCT04570995Wake Forest University Health Sciences22